research use only

Tafamidis 5-HT Receptor inhibitor

Cat.No.S6465

Tafamidis is a kinetic stabilizer of transthyretin (TTR) that prevents amyloidogenesis by wild-type and mutant TTRs.
Tafamidis 5-HT Receptor inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 308.12

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 308.12 Formula

C14H7Cl2NO3

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 594839-88-0 -- Storage of Stock Solutions

Synonyms N/A Smiles C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl

Solubility

In vitro
Batch:

DMSO : 31 mg/mL (100.61 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06086353 Recruiting
Transthyretin Amyloid Cardiomyopathy
Pfizer
March 25 2024 --
NCT05938218 Not yet recruiting
Amyloidosis Cardiac|Virtual Reality
Heinrich-Heine University Duesseldorf
December 1 2023 Not Applicable
NCT05489523 Recruiting
Transthyretin Cardiac Amyloidosis
University of Texas Southwestern Medical Center
May 1 2023 Phase 4
NCT05560555 Completed
Hereditary Transthyretin Amyloidosis (ATTRv)|Polyneuropathy
Pfizer
October 24 2022 --
NCT05374564 Recruiting
Cardiomyopathies Primary
Yale University|Pfizer
August 16 2022 Phase 1
NCT04814186 Completed
Transthyretin Amyloid Cardiomyopathy
Pfizer
July 22 2021 Phase 4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map